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LARGININE, BUT NOT LNAME PROTECTS AGAINST LIVER INJURY INDUCED
BY EXPERIMENTAL ISCHEMIAREPERFUSION
 O. M. Oleshchuk, K. A. Posokhova, A. Ye. Mudra
I. YA. HORBACHEVSKY TERNOPIL STATE MEDICAL UNIVERSITY, TERNOPIL, UKRAINE
Background. Hepatic ischemia-reperfusion (I/R) injury occurs upon restoration of hepatic blood flow after
a period of ischemia.
Objective. The study establishes that stimulation or blockade of nitric oxide synthesis has a protective
effect during ischemia-reperfusion.
Methods. Male albino rats which were divided into four equal groups: sham-operated control, ischemia
and reperfusion group (0.9 % saline i.p.) for 3 days, group pre-treated with L-arginine (25 mg/kg i.p.), group
pre-treated with L-NAME (10 mg/kg i.p.) for 3 days before ischemia-reperfusion maneuver. Complete ischemia
of the median and left hepatic lobes was induced by clamping the left branches of the portal vein and the
hepatic artery for 45 min. Rats were sacrificed after 3-h reperfusion. Nitric oxide synthase 3 (endothelial) and
nitric oxide synthase 2 (inducible) expression, nitric oxide stabile metabolites (NO2, NO3) content, AST and ALT
activities were determined. Histological examination of liver tissue was performed.
Conclusions. Relative NO deficiency, due to eNOS inhibition, is central in the pathogenesis of hepatic
ischemia reperfusion injury. Replacing NO content with either precursors or via donor drugs represents novel
methods in ameliorating ischemia-reperfusion injury.
KEY WORDS: hepatic ischemia-reperfusion, nitric oxide, NOS isoforms, L-arginine, L-NAME.
Introduction
Ischemia-reperfusion (I/R) of the liver is a
complex of pathophysiological processes that occurs
during surgery, trauma, liver transplantation and can
lead to serious liver injury. Basic mechanisms of liver
IR are not completely understood at present time,
but we claim that reactive oxygen and nitrogen are
important in this process. Overproduction of free
radicals by activated Kupffer cells and neutrophils
causes a number of toxic effects, including changes
in lipid and protein oxidation, excretion of proin-
flammatory mediators and microvascular dysfun-
ction, which together lead to cell and tissue damage
[1]. According to Bahde H. (2010), the hepatic
microcirculation violations and endothelial dysfun-
ction also play main role in the pathophysiology of I/
R at the time of reperfusion [2]. The biologically active
molecule of nitric oxide (NO) may play a pivotal role
in the process of free radicals formation.
However, the data about the protective or
damaging role of NO during I/R are controversial.
According to some studies the application of NO
precursors minimizes the adverse effects of
reperfusion and improves hepatic microcirculation
[3,4]. On the other hand, studies of some researchers
suggest that inhibitors of NO synthesis can prevent
liver damage during I/R [5].
This study shows that stimulation or blockade
of nitric oxide synthesis has a protective effect during
ischemia-reperfusion.
Methods
NO precursor – L-arginine and non-selective
NOS blocker – L-NAME (N-nito-L-arginine methyl
ester) were procured from Sigma; alanine amino-
transferase (ALT) and aspartate aminotransferase
(AST) kits were procured from “Filisit–diagnostic”,
while TNF-, IL-1, IL-6, eNOS, and iNOS ELISA
kits were procured USCN Limited Inc.
Animal model
Male white rats (Ternopil State Medical Uni-
versity vivarium, Ukraine) 8 to 10 weeks old, were
used for these experiments. All animals were fasted
12 h before experimentation and allowed water ad
libitum. All animals received care in compliance with
the “Guide for the Care and Use of Laboratory
Animals” (National Institute of Health Publication
№ 85-23, revised 1985). The studies were carried
out according to the National Institute of Health Guide
for the Care and Use of Laboratory Animals and were
approved by the local animal protection committee.
Induction of ischemic and reperfusion injury
The hepatic ischemia-reperfusion (I/R) protocols
were performed as described in a previous study by
Oleshchuk, 2012 [6]. There was no mortality
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observed associated with this model. The liver of
each rat was exposed through a midline laparotomy
after the induction of anesthesia (thiopental sodium
20 mg/kg i.p.). Complete ischemia of the median
and left hepatic lobes was induced by clamping the
left branches of the portal vein and the hepatic artery
for 45 min. The right hepatic lobe was perfused to
prevent intestinal congestion. After the time frame
sufficient for ischemia development, the ligatures
around the left branches of the portal vein and hepatic
artery were removed. In order to accurately evaluate
the blood flow in the median and left hepatic lobes
after ischemia, the right branches of the portal vein
and the hepatic artery were ligated to prevent
shunting to the right lobe after reperfusion and
perfused for 2 h. The wound was stitched with 3.0
silk suture. Sham-operated animals were similarly
prepared except that no ligature was placed to
obstruct the blood flow to the left and median hepatic
lobes. Instead, it the blood flow to the right lobe of
the liver was occluded. Rats were sacrificed in all
groups after 1-h ischemia followed by 3-h reper-
fusion. Twenty four white rats were divided into four
equal groups (n=6 each group). Group 1 (sham-
operated control group) and group 2 (ischemia and
reperfusion group) were given 0.9 % saline (1 mL/kg,
i.p.) for 3 days. Group 3 was pre-treated with
L-arginine (25 mg/kg i.p.), group 4 – with L-NAME
(10 mg/kg i.p.) for 3 days before, (last time – 10 min
before) induced ischemia-reperfusion maneuver.
Peripheral blood and hepatic tissue procurement
Blood sampling for determination of liver
enzymes. Blood samples were obtained from the
right ventricle via left anterior thoracotomy at the time
of sacrifice. Blood was collected in a sterile syringe
without anticoagulant and centrifuged at 2000 g to
separate the serum. The serum samples were stored
at -20 °C until use for AST and ALT assays.
Blood sampling for cytokine and NOS deter-
mination. Serum was removed from blood samples
by clotting for 2 hours on ice; serum was centrifuged
at 2,500g (4 °C), filtered, aliquoted, and frozen at
-20 °C until assayed for eNOS and iNOS. Small liver
samples were collected from each rat, then frozen
immediately and stored in liquid nitrogen until used
for eNOS and iNOS assays.
Determination of liver enzymes function
Determination of AST (EC 2.6.1.1) and ALT (EC
2.6.1.2) in plasma was performed by Raytman-
Frenkel method, using a standard kit “Filisit-
diagnostic” (Ukraine) according to the manufacturer’s
instructions. The activity of AST and ALT in serum
were expressed in mmol/( Lh).
NO
2
 and NO
3
 assays.
NO
2
 and NO
3 
in serum of blood and liver homo-
genates (1:10) were determined as described by
several authors [7].
NOS assays
Determination of eNOS activity was performed
by ELISA method using “Enzyme-linked Immu-
nosorbent Assay Kit for Rat Nitric Oxide Synthase
3, Endothelial (NOS3)”, USCN, Life Science Inc,
E90868Ra.
Determination of iNOS activity was done by
ELISA method using “Enzyme-linked Immu-
nosorbent Assay Kit for Rat Nitric Oxide Synthase
2, Inducible (NOS2)”, USCN, Life Science Inc,
E90837Ra.
eNOS and iNOS expression was investigated
in blood plasma and liver tissue. Blood was collected
using EDTA as an anticoagulant. Samples were
centrifuged for 15 min at 1000 g/min at 2–8 °C within
30 min after collection. Determination was carried
out immediately or frozen at -20 °C.
The procedure of liver cells lysis was performed
as follows:
1. Preparing liver homogenates in isotonic NaCl
solution at a ratio of 1:10.
2. Liver cells were centrifuged for 5 min at 300 g,
and then the supernatant was removed.
3. Cells were washed twice with isotonic NaCl
solution, after each wash the suspension was centri-
fuged at 300 g for 5 min.
4. Buffer (PBS) was added to the normal liver
tissue lysate (1 ml of buffer at 1106 liver cells). It
was centrifuged for 5 min at 300 g.
5. The supernatant was collected. Determination
of enzyme activity was carried out immediately or
the supernatant was frozen at -20 °C.
Determination of eNOS and iNOS concentration
were performed by ELISA method and according to
the manufacturer’s instruction. eNOS activity in
serum and in hepatocytes (1 ml – 1106 cells) was
expressed as U/ml, and iNOS activity was expressed
as ng/ml.
Histopathology study
A portion of the tissue from the ischemic liver
lobe was fixed in 10 % neutral-buffered formalin
solution for 5 days, embedded in paraffin, and
sectioned. The sections were stained with hema-
toxylin and eosin.
Statistical analysis
Statistical analysis was carried out by OriginPro
Program. Results are expressed as mean±standard
deviation. Differences between experimental groups
were analyzed with an unpaired 2-tailed Student
t test. All differences were considered statistically
significant at a p<0.05.
Results
The results indicate that after 45 min post-
ischemia followed by 2 h reperfusion the activity of
ALT in blood increased from (0.44±0.10) in the sham
control group compared to (2.35±0.09) in I/R group
O. M. Oleshchuk et al.
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animals, which is 5.3 times increase. Accordingly,
AST activity increased from (1.63±0.12) to (4.27±
0.37), which is 2.6 times increase. The described
dynamics indicates that cytolysis process of
hepatocytes is evolving under simulated IR injury
(Table 1).
The significant increase in ALT and AST activi-
ties, that occurred in I/R group, was significantly sup-
pressed by pre-treatment with 25 mg/kg L-arginine
(Table 1). Thus, the transaminases activity was
significantly lower: ALT (53.2 %) and AST (33.6 %).
The activity of ALT and AST increased by 38 % and
84 % with the introduction of L-NAME compared to
those of animals with the I/R alone. The activity of
these enzymes was different from the control values
by 7.4 and 4.8 times, respectively. This highlights a
further progression of cytolysis and output of
enzymes from the damaged hepatic tissue as a result
of L-NAME pre-treatment.
Therefore, it was found that stimulation of NO
synthesis in the animals with I/R improved function
of the liver and blockage of NO synthesis by nonse-
lective NOS inhibitor L-NAME aggravates liver injury.
Stimulated iNOS activity was registered in I/R
treatment, content of which in the liver increased by
57.6 %, while in the serum – by 185.0 %. Whereas,
the concentration of eNOS in the liver was reduced
by 38.5 % and in the blood by 18.2 % compared
with the group 1 (Table 2).
These changes took place on the background
of a decline in serum levels of stable metabolite of
nitric oxide NO
2
– by 51.7 %. This value has not
changed significantly in the liver relative to the control
group of similar animals. The level of NO
3
– in the
blood did not change significantly compared to the
liver where it was reduced by 65.5 % (Table 3).
Quantitative indicators can be evaluated as a
manifestation of a decrease in the total content of
final metabolites of NO in both blood and liver during
I/R trial.
The intensity of metabolism of nitric oxide under
conditions of prophylactic administration of its
precursor was evaluated by the concentration of its
stable metabolites (Table 3) and the activity of NO-
synthase isoforms (Table 2).
The level of nitric oxide metabolites in the blood
increased: NO
2
– – by 3.7 times, and NO
3
– – by
31.7 %, respectively, after administration of L-ar-
ginine, and in liver homogenates the content of nitrite
anion was not changed (p>0.05), and the nitrate
anion increased respectively by 3.1 times.
We observed one-way influence of the sub-
stance on the expression of NO-synthase isoforms,
both in blood and in the liver. Enzyme immunoassay
results showed that the use of L-arginine in I/R
treatment leads to increased eNOS content in
hepatocytes (43.5 %) and the reduction of iNOS
(19.2 %) (Table 2). A similar pattern was observed
Table 1. Effect of L-arginine on ALT and AST activity in the liver of sham and experimental groups of rats
Results are expressed as mean±SD (n=6); significantly different: p – from sham, p1 – from I/R injury group; activity of ALT
and AST are expressed in mmol/(l´h)
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in blood. Inducible NO-synthase was reduced by
24.8 % after the use of L-arginine, but remained
higher by more than 2.1 times, compared with sham
group of animals. Endothelial isoform of the enzyme
increased by 34.5 % compared to its value in group
1. To summarize, we can say that prophylactic admi-
nistration of NO precursor L-arginine before I/R was
followed by the activation of a constitutive NO-
synthase, with a simultaneous decrease of inducible
NOS activity and increase in nitric oxide metabolites
level.
It is logical that the expression of both isoforms
of nitric oxide synthase, on the background of
inhibition of L-NAME, decreased eNOS content was
even lower than in the group of animals without
correction by 56.5 and 38.5%, and the expression
of iNOS decreased by 55.9 and 39.3 % in blood and
hepatocytes.
Therefore, L-NAME reduced expression of all
NOS forms (Table 2). It was also shown that the
level of nitrite and nitrate anions after administration
of non-selective blocker of NO synthesis decreased
by 45.0 and 12.6% in the serum and by 41.1 and
46.0 % in liver homogenates compared to IR. The
levels were also significantly lower in the affected
organ (by 1.7 and 1.8 times) compared to the group
1 of animals. We can hypothesize that reduction of
end metabolites of nitric oxide synthesis correlates
with inhibition of NO synthase expression in both
serum and liver (Table 3).
During histological examination of liver tissue of
animals, which previously were administered L-
arginine and subsequently simulated ischemia-
reperfusion, we found that the trabecular structure
of the liver lobules was preserved. The central veins
were dilated and well visualized. Periportal areas had
lymphocytic and histiocytic infiltration, particularly
around the bile duct (Fig.1).
Histological examination of liver tissue in
ischemia-reperfusion model on the background of
the previous L-NAME administration showed that the
trabecular structure of the liver lobules was
significantly changed (Fig. 2).
Sinusoids were greatly expanded and they were
free from red blood cells in central lobular areas.
Narrowed and saturated cell macrophages in the
central and peripheral parts of the liver lobules were
not present as well. Portal tracts expanded mainly
due to the plethora of vessels and severe peri-
vascular lymphocytic and histiocytic infiltration. Signs
of small droplets of fat and protein degeneration were
present. Enhanced bile ducts and the presence of a
Table 3. NO2
– and NO3
– content in liver and blood of sham and experimental groups
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Fig. 1. Histological structure of the liver after administration
of L-arginine in ischemia-reperfusion injury. Hematoxylin-
eosin. Magnification power 160.
Fig. 2 Histological structure of the liver during ischemia-
reperfusion and application of L-NAME. Hematoxylin-eosin.
Magnification power 160.
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small amount of bile can be estimated as intrahepatic
cholestasis. A large number of cells with pyknotic
nuclei and necrotic cells were observed during
histological observation in periportal zone of acinus.
Discussion
I/R is a series of multifaceted cellular events
which take place on the resumption of oxygen deli-
very to the affected organ after a period of hypoxia.
IR occurs in the liver during procedures that are
associated with vascular inflow obstruction followed
by restoration of blood flow. I/R may result in major
hepatocellular damage [8].
NO plays a significant role in the acute phase of
I/R, as this phase is associated with a rapid decrease
in available NO. This decrease occurs either by
depressed production by eNOS in sinusoidal endo-
thelial cells, increased degradation by reactive
oxygen species, or both [9]. In this I/R study expres-
sion of liver iNOS increased and eNOS level de-
creased. It was determined during our previous I/R
studies that the levels of IL-1, IL-6 and TNF- in
I/R were significantly increased [6]. Therefore,
cytokines provoked stimulation of iNOS expression.
To summarize, there is a lack of synthesis of NO
during the early periods of reperfusion, which may
be due to inhibition of eNOS [9]. As for this study,
we have found that after 2 hours of reperfusion levels
of nitrates do not change significantly in the blood
with decrease in the liver, and conversely decreased
blood nitrite levels.
We have shown that the application of
L-arginine during I/R trial causes activation of nitric
oxide synthesis. Increased concentrations of NO
stable metabolites nitrite and nitrate anions in both
blood and liver is consistent with our previous results
and other scientific data [10, 11]. We observed one-
way impact on the content of NO-synthase isoform
in blood and in the liver. The level of endothelial form
increased and inducible – declined. Results of our
histological studies have shown that the precursor
of nitric oxide synthesis has protective influence on
the morphological structure of hepatocytes.
Blocking the enzymatic synthesis of NO in liver
I/R led to the aggravation of the pathological process,
as evidenced by the results of our biochemical and
histological studies.
Thus, the introduction of non-selective blocker
of NOS L-NAME increased activity of ALT and AST,
indicating a further increase cytolysis of hepatocytes
and this is consistent with L. M. Wang et al. (2003)
[12]. Our results on the liver degradation by complete
blocking enzymatic NO formation during I/R suggest
NO protective role during early reperfusion.
Conclusion.
Ischemia reperfusion injury is a well-defined
threat to the liver during periods of interruption and
restoration of oxygen delivery. It occurs in certain
procedures such as hepatic resections and
orthotopic liver transplantation. Relative NO
deficiency, due to eNOS inhibition, is central in the
pathogenesis of this injury. Replacing NO per se
either precursors or via donor drugs represents a
novel method for ameliorating hepatic ischemia-
reperfusion injury.
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